Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.59 |
| ▸ | MMP9 | P14780 | 17/20 | 0.59 |
| ▸ | MMP3 | P08254 | 4/20 | 0.56 |
| ▸ | MMP13 | P45452 | 3/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378575 | 1.00 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4654577 | 1.00 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL9248117 | 0.93 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL12300384 | 0.93 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL2380986 | 0.93 | MMP2 (0.61) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6291932 | 0.89 | MMP2 (0.48) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6296089 | 0.88 | GSK3B (0.55) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7865124 | 0.88 | TSHR (0.58) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8504009 | 0.87 | MMP2 (0.55) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7639741 | 0.85 | CYP1B1 (0.47) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | claimed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | claimed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0937036-B1 | SUBSTITUTED 4-BIPHENYL-4-HYDROXYBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER AG (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0937036-A1 | SUBSTITUTED 4-BIPHENYL-4-HYDROXYBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998022436-A1 | SUBSTITUTED 4-BIPHENYL-4-HYDROXYBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |